[{"orgOrder":0,"company":"Ginefiv","sponsor":"Theramex","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Ginefiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginefiv \/ Theramex","highestDevelopmentStatusID":"11","companyTruncated":"Ginefiv \/ Theramex"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"FHI 360","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ FHI 360","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ FHI 360"}]

Find Clinical Drug Pipeline Developments & Deals for Depo Provera

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Ginefiv

                          Country arrow
                          EPSC
                          Not Confirmed

                          Ginefiv

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Theramex

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The expanded collaboration is expected to deliver more than 320 million doses of Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate) administered by BD Uniject™ Auto-Disable Prefillable Injection System, through 2030.

                          Product Name : Sayana Press

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          March 08, 2023

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Bill & Melinda Gates Foundation

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 23, 2020

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : FHI 360

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 09, 2018

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : FHI 360

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Asan Medical Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Asan Medical Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          June 26, 2018

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Korean Gynecologic Oncology Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Galeno Desenvolvimento de Pesquisas Clínicas

                          Country arrow
                          EPSC
                          Not Confirmed

                          Galeno Desenvolvimento de Pesquisas Clínicas

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          February 22, 2018

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : Biolab Sanus Farmaceutica

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 29, 2016

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : FHI 360

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          FHI 360

                          Country arrow
                          EPSC
                          Not Confirmed

                          FHI 360

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Undisclosed

                          Sponsor : University of Washington | Wits Reproductive Health and HIV Institute | World Health Organization | Madibeng Centre for Research | Maternal Adolescent and Child Health Research | Qhakaza Mbokodo Research Clinic | The Aurum Institute NPC | Effective Care R

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          September 15, 2015

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : University of Washington | Wits Reproductive Health and HIV Institute | World Health Organization | Madibeng Centre for Research | Maternal Adolescent and Child Health Research | Qhakaza Mbokodo Research Clinic | The Aurum Institute NPC | Effective Care R

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Planned Parenthood Federation of America

                          Country arrow
                          EPSC
                          Not Confirmed

                          Planned Parenthood Federation of America

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          July 28, 2015

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase IV

                          Sponsor : Pfizer Inc | Tara Health Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          FHI 360

                          Country arrow
                          EPSC
                          Not Confirmed

                          FHI 360

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Study Phase : Phase I

                          Sponsor : Oregon Health and Science University | Asociación Dominicana Pro Bienestar de la Familia, Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          May 28, 2015

                          Lead Product(s) : Medroxyprogesterone Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : Oregon Health and Science University | Asociación Dominicana Pro Bienestar de la Familia, Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank